Auro Laboratories Ltd (530233) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 530233 | NSE: | Pharmaceuticals & Drugs | Small Cap

Auro Laboratories Share Price

254.10 -2.60 -1.01%
as on 05-Dec'25 12:16

Auro Laboratories Ltd (530233) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 530233 | NSE: | Pharmaceuticals & Drugs | Small Cap

DeciZen - make an informed investing decision on Auro Laboratories

Based on:

Overall Rating
Login to view analysis. M-Cap below 500cr. High Risk from low Liquidity Bole Toh

1. Quality


Login to view analysis.

2. Valuation


Login to view analysis.

3. Price Trend


Login to view analysis.

Auro Laboratories stock performance -

Key Ratios
mw4me loader
P/E Ratio (SA):
151.36
Market Cap:
160 Cr.
52-wk low:
159
52-wk high:
303

Is Auro Laboratories Ltd an attractive stock to invest in?


Login to view analysis.

10 Year X-Ray of Auro Laboratories: Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Auro Laboratories Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Value Creation Index Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 11.2%20.2%28.7%29.1%24.8%38.9%12.2%9.9%20.4%3.8%-
Value Creation
Index
-0.20.51.11.10.81.8-0.1-0.30.5-0.7-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 27.935.540.846.843.854.350.952.953.619.422
Sales YoY Gr.-27.1%15%14.8%-6.5%23.9%-6.2%4%1.4%-63.8%-
Adj EPS 10.85.26.15.510.93.7310.92.31.7
YoY Gr.--24.3%561.5%18%-9%96.2%-65.7%-20.1%265.4%-78.9%-
BVPS (₹) 13.815.120.827.934.545.950.654.967.368.969.9
Adj Net
Profit
0.60.53.23.83.56.82.31.96.81.41
Cash Flow from Ops. 7.95.94.86.99.312.8-6.63.318.85.8-
Debt/CF from Ops. 1.61.71.91.20.30.3-2.121.47.8-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales -4%-15%-27.5%-63.8%
Adj EPS 9.3%-16.1%-14.9%-78.9%
BVPS19.6%14.9%10.9%2.4%
Share Price 26.8% 25.4% 49.8% 5.2%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
7.95.428.72517.727.17.75.717.83.42.5
Op. Profit
Mgn %
1012.515.614.914.320.79.18.319.917.616.5
Net Profit
Mgn %
2.31.47.98.17.912.54.63.512.77.44.8
Debt to
Equity
1.51.10.70.50.20.10.40.20.61.10.7
Working Cap
Days
18812411911211287139202212471110
Cash Conv.
Cycle
913929373920588481109-29

Recent Performance Summary

Login to view analysis.
Login to view analysis.

Latest Financials - Auro Laboratories Ltd.

Standalone Consolidated
TTM EPS (₹) 1.7 -
TTM Sales (₹ Cr.) 22.1 -
BVPS (₹.) 69.9 -
Reserves (₹ Cr.) 37 -
P/BV 3.67 -
PE 151.36 -
From the Market
52 Week Low / High (₹) 159.00 / 303.00
All Time Low / High (₹) 0.70 / 307.20
Market Cap (₹ Cr.) 160
Equity (₹ Cr.) 6.2
Face Value (₹) 10
Industry PE 40.7

Management X-Ray of Auro Laboratories:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Auro Laboratories - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios of Auro Laboratories

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales28354147445451535419
Operating Expenses 25313440384346494316
Manufacturing Costs2333343441
Material Costs1822252924293336279
Employee Cost 2333344442
Other Costs 3345676683
Operating Profit 346761154113
Operating Profit Margin (%) 10.0%12.5%15.6%14.9%14.3%20.7%9.1%8.3%19.9%17.5%
Other Income 0111111121
Interest 2111101111
Depreciation 1111111111
Exceptional Items 0000000000
Profit Before Tax 135661143102
Tax 0212231130
Profit After Tax 1144473282
PAT Margin (%) 3.2%2.3%8.7%9.4%9.3%13.2%5.6%4.6%14.5%9.5%
Adjusted EPS (₹)1.41.35.77.16.511.54.63.912.53.0
Dividend Payout Ratio (%)0%0%0%0%0%0%0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund 991317212932344243
Share Capital 6666666666
Reserves 23711152225283637
Minority Interest0000000000
Debt131098331362643
Long Term Debt7106532221833
Short Term Debt503401124810
Trade Payables45555651166
Others Liabilities 13333554116
Total Liabilities 26273033324255568699

Fixed Assets

Gross Block15202123242425253636
Accumulated Depreciation6789101112131415
Net Fixed Assets 9131315141414132221
CWIP 301000483356
Investments 0000000000
Inventories41134341284
Trade Receivables5889671412139
Cash Equivalents 112461512221
Others Assets 3443247988
Total Assets 26273033324255568699

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity 8657913-73196
PBT 135661143102
Adjustment 2222212222
Changes in Working Capital 52-1-121-12-262
Tax Paid 0-1-10000000
Cash Flow From Investing Activity -2-2-2-3-2-4-5-5-39-24
Capex -30-2-2-1-0-5-4-36-24
Net Investments 0000000000
Others 0-20-2-2-3-1-1-3-1
Cash Flow From Financing Activity -5-4-2-2-6-010-81918
Net Proceeds from Shares 0000000000
Net Proceeds from Borrowing -0-10-1-1-0-011715
Interest Paid -2-1-1-1-1-0-1-1-1-1
Dividend Paid 0000000000
Others -4-2-1-0-4011-834
Net Cash Flow 001229-2-10-1-1

Finance Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)10.839.0631.5328.9520.8428.679.477.4320.464.33
ROCE (%)11.2120.2428.6529.1224.838.8812.29.9220.373.79
Asset Turnover Ratio1.081.411.431.471.331.461.050.950.760.21
PAT to CFO Conversion(x)861.251.752.251.86-2.331.52.383
Working Capital Days
Receivable Days846372666044759088214
Inventory Days612813193122245568112
Payable Days7169766774675984122246

Auro Laboratories Ltd Stock News

Auro Laboratories Ltd FAQs

The current trading price of Auro Laboratories on 05-Dec-2025 12:16 is ₹254.1.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 04-Dec-2025 the market cap of Auro Laboratories stood at ₹160.0.
The latest P/E ratio of Auro Laboratories as of 04-Dec-2025 is 151.4.
The latest P/B ratio of Auro Laboratories as of 04-Dec-2025 is 3.67.
The 52-week high of Auro Laboratories is ₹303.0 and the 52-week low is ₹159.0.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Auro Laboratories is ₹22.07 ( Cr.) .

About Auro Laboratories Ltd

Auro Laboratories incorporated in 1989 is engaged in business of manufacturing active pharmaceutical ingredients (API's), intermediates and generic formulations. The company is promoted by Shri Sharat Deorah and Shri Satish Deorah.

Company’s manufacturing facility is located at Tarapur in the state of Maharashtra. This facility is well supported by quality control laboratory and common effluent treatment plant (CETP). The Company started commercial production of this facility on 14th July, 1992. The manufacturing facility has an installed capacity in excess of 500 tonnes per annum.

Company is primarily focused on manufacturing anti-diabetic drugs. Presently company caters its products in therapeutic segment such as antihistamine, anti-fungal, anti-ulcer, anti-malaria, anti-inflammatory, antacids and others.   Company exports its products in countries like Egypt, Germany, Malaysia, Singapore, South Africa, Brazil, Spain and United Kingdom. Auro Laboratories received ISO 9001:2000 and WHO - cGMP certifications for its quality management.

Products

APIs- Under this company manufactures drugs like Chlorpheniramine Maleate, Chlorzoxazone, Metformin HCl, Potassium Iodate, Magnesium Hydroxide and many more.

Under specialty chemicals company manufactures Guanidine Nitrate, Dimethyl Amine HCl, 2-Ethoxy Benzoic Acid and 3,4,5, Trimethoxy Benzoic Acid.

Intermediate- Company manufactures products such as Glibenclamde Sulphonamide, Cis-bramo benzoate, Cls-Tosylate, Cis-bramo benzoate, 3, 4, 5 - Trimethoxy Benzoic Acid, 2-Ethoxy Benzoic Acid and  5-Bromo Phthalide

Milestones

1992- Company started manufacturing of Sodium Citrate and Potassium Iodide. Company developed antibacterial drug, Trimethoprim.

1996- Company commenced manufacturing of 3,4,5 Trimethoxy Benzaldehyde, which is the basic raw material for Trimethoprim. Company was listed on Bombay Stock Exchange (BSE).

2004-Company received ISO 9001:2000 certification.

2006-Company received certificate of suitability (cos) from the European Directorate of Quality Medicine (EDQM).

2007- Company received DMF No 19910 from the FDA for Metformin Hydrochloride.

Future plansAuro Laboratories plans to widen its product portfolio to strengthen its position in the market.

To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×